Related Experiment Videos
Medroxyprogesterone in metastatic renal cell carcinoma
Southern Medical Journal
|February 1, 1980
Summary
Medroxy-progesterone acetate (Depo-Provera) achieved complete regression of pulmonary metastases in a renal cell carcinoma (RCC) patient. This progesterone therapy, despite a low objective response rate, warrants consideration for RCC treatment, especially in men.
Area of Science:
- Oncology
- Endocrinology
- Medical Research
Background:
- Renal cell carcinoma (RCC) is a significant cancer with limited treatment options for metastatic disease.
- Pulmonary metastases from RCC often indicate advanced disease and a poor prognosis.
- Standard therapies for metastatic RCC can be toxic and yield limited responses.
Observation:
- A case study details a patient with advanced renal cell carcinoma (RCC) presenting with pulmonary metastases.
- The patient received treatment with medroxy-progesterone acetate (Depo-Provera).
Findings:
- Complete regression of pulmonary metastases was observed following treatment with medroxy-progesterone acetate.
- While objective response rates for progesterone therapy in RCC are typically 10%–15%, this case demonstrates a dramatic positive outcome.
- This contrasts with other, more toxic agents that failed to provide significant responses in similar cases.
Implications:
- Medroxy-progesterone acetate (Depo-Provera) may represent a viable, less toxic treatment option for select patients with metastatic renal cell carcinoma (RCC).
- The potential for dramatic responses, particularly in male patients, suggests further investigation into progesterone therapy for RCC is warranted.
- This case highlights the importance of considering hormonal therapies in the management of advanced renal cell carcinoma (RCC).